First-line treatment in line with stem cell transplantation of the new diagnosis of multiple myeloma! Johnson and Johnson Darzalex (Mega®) and RVd solution demonstrate severance!

April 26, 2020 /
Biovalley BIOON/ -- For new patients with multiple myeloma (NDMM) who meet the conditions for transplantation, self-
stem cell transplantation (ASCT) is a standard first-line therapy after treatment with the Rhonamine, boronitomi and dexamethasone programmes (RVd) A recent study published in Blood, a leading international journal in hematology, showed that the Johnson and Johnson anti-cancer drug Darzalex (Chinese: mega-®, generic name: daratumab, Daretou monoantigen) and RVd combined drug regimen (D-RVd) can significantly improve efficacy and no new safety issues compared to the RVd program The article was titled: Daratumumab, Lenalidomide, Bortezomib, sdexamethaone for Tranplant-eligible New Diagnoed Multiple Myeloma: GRIFFIN GRIFFIN (NCT02874742) is a randomized, open label Phase II study conducted in NDMM patients who meet high doses of chemotherapy and ASCT to assess the efficacy and safety of D-RVd and RVd protocols In the study, patients were randomly divided into 2 groups with a ratio of 1:1, with one group receiving D-RVd induction (2 cycles), ASCT, D-RVd consolidation (2 cycles), D-to-rhamine maintenance therapy (26 cycles), and the other group receiving RVd induction (2 cycles), ASCT, RVd consolidation (2 cycles), and naramine maintenance therapy (26 weeks) results show that in the primary endpoint analysis, the At the end of ASCT post-consolidation therapy, the strict total remission rate (CR) in the D-RVd group was higher than that of the RVd group (42.4% v 32.0% ; the ratio of the ratio was 1.57, 95% CI: 0.87-2.82; the one-sided p-0.068), in line with the pre-specified one-sided alpha of 0.1 with the extended follow-up time (median: 22.1 months), the mitigation continued to deepen , and the D-RVd group OF CRs continued to improve compared to RVd (62.6% v 45.4% ;p 0.0177), and the microresidual disease negative rate (threshold: -5 side) of the intentional treatment population (ITT) also showed an increase of ;p 0.00 00%.00000 There were 4 cases (3.8%), 7 (6.8%) in the RVd group, and 95.8% (D-RVd group) and 89.8% (RVd group) in 24 months level 3/4 hematological adverse events were more common in the D-RVd group The D-RVd group had a higher infection rate, but a similar rate of infection at level 3/4 The number of bit slot slot s /g in the D-RVd group was 8.2 x 10 for 6 squares/kg, and in the RVd group for 6 squares/kg of 9.4 x 10, but plerixafor in the D-RVd group was more common There was no difference in the median time of neutrophils and platelet sittolet , compared with RVd, D-RVd induction and consolidation improved the remission depth of NDMM patients eligible for transplantation, with no new safety issues, and no clinically significant effects on the mobilization and implantation of stem cells Darzalex (mega
®, Darettou monoantigen ): The world's first CD38 target monoantigen, and then definemyeloma treatment multiple myeloma (MM) is an incurable blood system malignant tumor characterized by recurrent recurrent recurrent The disease is a highly invasive disease that affects plasma cells in the bone marrow, which replace normal cells in the bone marrow It is estimated that 32,270 people will be diagnosed and 12,830 will die from the disease by 2020 Although some MM patients have no symptoms, most are diagnosed with symptoms, including fractures or pain, low red blood cell count, fatigue, high calcium levels, kidney problems, or infections Darzalex was first approved for the market in November 2015 as the world's first CD38-mediated, cysototic antibody drug with broad-spectrum killer activity that targets transmembrane extracellular cd3, which is highly expressed in combination with multiple myeloma and multiple solid tumor cell surfaces 8 molecules, induced by a variety of immunomediated mechanisms to induce rapid death of tumor cells, including complementary dependent cytotoxic action (CDC), antibody-dependent cell-mediated cytotoxic action (ADCC) and antibody-dependent cell phagocytosis (ADCP), and apoptomy In addition, Darzalex has been shown to target immunosuppressive cells in the tumor microenvironment to demonstrate immunomodulatory activity in the United States, Darzalex has been approved for seven treatments for indications, three of which are first-line treatment sedatives Currently, Darzalex has become an important basic therapy for the treatment of multiple myeloma (MM), which has entered the first-line treatment of new PATIENTs with MM (including: eligible and ineligible for ASCT new treatment MM), second- and multi-line treatment of relapsed or difficult MM patients in China, Darzalex (Mega®, Daretou monoantigen) was approved for the october 2019 and is intended for single-drug treatment for adult patients with recurrent and refractive multiple myeloma, as follows with previous treatments including protease inhibitors and immunomodulators and progressof the disease at the last treatment As China's first approved CD38 monoclonal antibody target drug, this innovative program is expected to redefine the treatment of multiple myeloma in the country (BiovalleyBioon.com) original origin: Daratumumab, Lenalidomide, Bortezomib, and Dexamethaone for Tranplant-eligible Diagnoed Myeloma: GRIFFIN